Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LncRNA XLOC_075168 to preparation of medicines for promoting angiogenesis

An angiogenesis and drug technology, applied in the field of cell engineering and genetic engineering, to achieve the effect of reducing the rate of apoptosis

Active Publication Date: 2019-10-29
GUANGDONG LAB ANIMALS MONITORING INST +1
View PDF9 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, many literatures have reported that lncRNA affects angiogenesis by regulating human umbilical vein endothelial cells (HUVECs) in tumor diseases, but angiogenesis after MI is rarely reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LncRNA XLOC_075168 to preparation of medicines for promoting angiogenesis
  • Application of LncRNA XLOC_075168 to preparation of medicines for promoting angiogenesis
  • Application of LncRNA XLOC_075168 to preparation of medicines for promoting angiogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] 1. Construction of gene overexpression vector

[0031] The lncRNA XLOC_075168 related to myocardial infarction was selected from the differential lncRNA as the research object. DNAMAN software analysis found that the full-length sequence of the lncRNA XLOC_075168 gene has no Kpn I and Nhe I restriction enzyme sites, while the pcDNA3.1(-) vector (purchased from BioMed, catalog number CL408-01) has Kpn I And Nhe I restriction site. The primer premier 5.0 software designs gene full-length primers, and its upstream and downstream primers are respectively added with Kpn I and Nhe I restriction site sequences. Using human umbilical vein endothelial cell cDNA as a template, the target fragment was amplified by PCR (the amplified target fragment is the sequence of lncRNAXLOC_075168, the nucleotide sequence of which is shown in SEQ ID NO. 1), purified and recovered, double enzyme digestion, and ligation of pcDNA3 .1 (-) Vector, transformation, screening, sequencing and identifica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of LncRNA XLOC_075168 to preparation of medicines for promoting angiogenesis. Overexpressing and silencing of lncRNA XLOC_075168 confirm that the lncRNA XLOC_075168 can influence the expression of an ATG7 gene and protein in human umbilical vein endothelial cells, also confirm that the lncRNA XLOC_075168 participates in promoting the proliferation of the human umbilical vein endothelial cells, restraining the apoptosis of the human umbilical vein endothelial cells and promoting the canaliculization of the human umbilical vein endothelial cells, and further illustrate that the lncRNA XLOC_075168 can possibly participate in promoting the angiogenesis after miocardial infarction. Therefore, the lncRNA XLOC_075168 or a reagent for promoting expression ofthe lncRNA XLOC_075168 can be used for preparing medicines for promoting angiogenesis and can particularly be used for preparing medicines for promoting angiogenesis after miocardial infarction.

Description

Technical field [0001] The invention belongs to the technical field of cell engineering and genetic engineering, and specifically relates to the application of a long-chain non-coding RNA XLOC_075168 (lncRNA XLOC_075168) or an agent for promoting its expression in the preparation of drugs for promoting angiogenesis. Background technique [0002] Myocardial infarction (MI) is a cardiovascular disease that seriously endangers human health. The disease is based on coronary atherosclerosis and the formation of blood clots obstructing the coronary artery lumen. Due to prolonged ischemia, myocardial necrosis is eventually caused. Called "the number one killer of human health." [0003] Angiogenesis refers to the new blood vessels that develop from existing capillaries or post-capillary veins. They mainly form fully functional blood vessels through sprouting and reproduction, including the proliferation, sprouting and migration of endothelial cells. In the damaged heart, effective vascul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7088A61P9/10
CPCA61K31/7088A61K45/00A61P9/10
Inventor 王希龙张豪潘金春袁晓龙龚宝勇唐龙龙高洪彬李加琪谭伟江张哲梁十
Owner GUANGDONG LAB ANIMALS MONITORING INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com